Claritev (NYSE:CTEV) Stock: Insider Tiffani Misencik Sells 5,812 Shares

Claritev (NYSE:CTEV) SVP Tiffani Misencik sold 5,812 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $23.81, for a total value of $138,383.72. Following the sale, the senior vice president directly owned 107,917 shares of the company’s stock, valued at approximately $2,569,503.77. This represents a 5.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tiffani Misencik also recently made the following trade(s):

• On Friday, August 14th, Tiffani Misencik sold 8,850 shares of Claritev stock. The stock was sold at an average price of $40.07, for a total value of $354,619.50.

Claritev Trading Down 7.5%

Shares of CTEV stock opened at $22.06 on Friday. The business’s 50 day moving average is $31.65 and its two-hundred day moving average is $27.55. Claritev has a twelve month low of $11.50 and a twelve month high of $73.68. The company has a market capitalization of $373.92 million, a P/E ratio of -1.30 and a beta of 0.93.

Claritev (NYSE:CTEV) last released its earnings results on Friday, August 7th. The company reported $1.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.10) by $5.51. The company had revenue of $257.48 million during the quarter. As a group, equities analysts predict that Claritev will post -15.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Claritev

A number of large investors have recently modified their holdings of the business. Engineers Gate Manager LP acquired a new stake in shares of Claritev in the 2nd quarter valued at approximately $245,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Claritev in the second quarter valued at approximately $44,000. Public Investment Fund purchased a new stake in shares of Claritev in the second quarter valued at approximately $43,703,438. FAS Wealth Partners Inc. boosted its stake in shares of Claritev by 49.5% in the first quarter. FAS Wealth Partners Inc. now owns 46,477 shares of the company’s stock valued at $759,000 after buying an additional 15,380 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in Claritev by 146.6% during the first quarter. Bank of America Corp DE now owns 97,795 shares of the company’s stock worth $1,598,000 after acquiring an additional 58,133 shares during the period. 87.15% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on CTEV shares. Piper Sandler reissued an “overweight” rating and issued a $73.00 price objective on shares of Claritev in a research note on Wednesday, August 12th. Wall Street Zen upgraded shares of Claritev from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Claritev in a research note on Monday, September 21st. Barclays restated an “overweight” rating and issued a $40.00 target price (up from $28.00) on shares of Claritev in a research note on Thursday, August 20th. Finally, Canaccord Genuity Group lifted their target price on shares of Claritev from $37.00 to $43.00 and gave the company a “buy” rating in a report on Monday, August 10th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $44.83.

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.